<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558672</url>
  </required_header>
  <id_info>
    <org_study_id>4060</org_study_id>
    <nct_id>NCT03558672</nct_id>
  </id_info>
  <brief_title>A Registry to Evaluate the Flexitouch System and Flexitouch Plus for Treatment of Head and Neck Lymphedema</brief_title>
  <official_title>A Registry to Evaluate the Flexitouch System and Flexitouch Plus for Treatment of Head and Neck Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tactile Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tactile Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this registry is to evaluate the long term effectiveness of the Flexitouch
      System and Flexitouch Plus in those with head and neck lymphedema. This outcome data will
      include information regarding each subject's medical history, symptoms, quality of life,
      pain, range of motion (ROM), swelling, ease of use, treatment satisfaction, treatment
      compliance, and adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Symptom Improvement</measure>
    <time_frame>Changes between Baseline and 6 months will be assessed</time_frame>
    <description>To evaluate symptoms based upon the EORTC HN35 questionnaire after 168 days (approximately 6 months) of treatment with the Flexitouch System or Flexitouch Plus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Function Improvement</measure>
    <time_frame>Changes between Baseline and 6 months will be assessed</time_frame>
    <description>To evaluate function based upon cervical and shoulder range of motions measurements after 168 days (approximately 6 months) of treatment with the Flexitouch System or Flexitouch Plus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related Quality of Life</measure>
    <time_frame>Changes between Baseline and 1, 3, and 6 months will be assessed</time_frame>
    <description>Subject Quality of Life will be assessed using EORTC C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pain</measure>
    <time_frame>Changes between Baseline and 1, 3, and 6 months will be assessed</time_frame>
    <description>Pain will be assessed using the VAS Pain Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swelling</measure>
    <time_frame>Changes between Baseline and 1, 3, and 6 months will be assessed</time_frame>
    <description>Swelling will be assessed using the ALOHA measurement protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Use and Treatment Satisfaction</measure>
    <time_frame>Assessed at 6 months</time_frame>
    <description>Both Ease of Use and Treatment satisfaction will be assessed by survey</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Head and Neck Lymphedema</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flexitouch system with Head and Neck Garments</intervention_name>
    <description>Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with Head and Neck Lymphedema and prescribed the Flexitouch system or
        Flexitouch Plus system as standard of care treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  A diagnosis of head and/or neck lymphedema

          -  Must be able and willing to participate in all aspects of the registry and provide
             informed consent prior to registry participation

          -  Head and chest measurements within the following:

          -  Crown of head circumference: ≤ 72 cm

          -  Chest circumference: ≤ 158 cm

          -  Prescribed the Flexitouch system or Flexitouch Plus

        Exclusion Criteria:

          -  Uncontrolled hyperthyroidism or parathyroidism (for which endocrinologist recommends
             against neck compression)

          -  Carotid sinus hypersensitivity syndrome

          -  Symptomatic carotid artery disease, as manifested by a recent transient ischemic
             attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual
             ischemic symptoms or blindness)

          -  Symptomatic bradycardia in the absence of a pacemaker

          -  Internal jugular venous thrombosis (within 3 months)

          -  Increased intracranial pressure or other contraindications to internal or external
             jugular venous compression

          -  Acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), or
             surgical flap less than 6-8 weeks post-operative

          -  Facial or head and neck dermal metastasis

          -  Acute facial infection (e.g., facial or parotid gland abscess)

          -  Any condition in which increased venous and lymphatic return is undesirable

          -  Heart failure (acute pulmonary edema, decompensated acute heart failure)

          -  Subject is pregnant or trying to become pregnant

          -  Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute
             pulmonary embolism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Stone</last_name>
    <phone>612-540-5267</phone>
    <email>astone@tactilemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tari Muenchow</last_name>
    <phone>612-540-7176</phone>
    <email>tmuenchow@tactilemedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Iowa ENT Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Hesse</last_name>
      <phone>515-223-4368</phone>
      <email>jhesse@iowaentcenter.com</email>
    </contact>
    <investigator>
      <last_name>Simon Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles George VA Medical Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Peyton</last_name>
      <phone>828-298-7911</phone>
      <email>leslie.peyton@va.gov</email>
    </contact>
    <investigator>
      <last_name>Julia Furdyna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Lemon</last_name>
      <phone>614-685-8964</phone>
      <email>brandi.lemon@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Buss</last_name>
      <phone>412-359-6411</phone>
      <email>megan.buss@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Youssef Arshoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flexitouch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 12, 2020</submitted>
    <returned>July 1, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

